+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dupixent"

From
DUPIXENT Market Size, Emerging Insight, and Forecast to 2032 - Product Thumbnail Image

DUPIXENT Market Size, Emerging Insight, and Forecast to 2032

  • Report
  • December 2024
  • 30 Pages
  • Global
From
Prescription Dermatological Drugs Global Market Report 2025 - Product Thumbnail Image

Prescription Dermatological Drugs Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
From
Chronic Spontaneous Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Spontaneous Urticaria- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Urticaria- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
From
From
From
From
Atopic Dermatitis - Competitive Landscape, 2023 - Product Thumbnail Image

Atopic Dermatitis - Competitive Landscape, 2023

  • Report
  • April 2023
  • 240 Pages
  • Global
From
From
From
Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032

  • Drug Pipelines
  • January 2022
  • 100 Pages
  • Global
From
Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Atopic Dermatitis Drugs Market - Forecasts from 2024 to 2029

  • Report
  • January 2024
  • 143 Pages
  • Global
From
Loading Indicator

Dupixent (dupilumab) is a biologic drug used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It is a monoclonal antibody that works by blocking two proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in the inflammation and symptoms of atopic dermatitis. Dupixent is administered as an injection under the skin (subcutaneous) every two weeks. The Dupixent market is a rapidly growing segment of the dermatological drugs market. It is a highly competitive market, with several companies offering similar products. Dupixent is the first biologic drug approved for the treatment of atopic dermatitis, and it has been shown to be effective in reducing symptoms and improving quality of life for patients. Companies in the Dupixent market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more